bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium

Author's Avatar
Jun 15, 2023

bioAffinity+Technologies%2C+Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for early-stage cancer detection and broad-spectrum cancer therapeutics, will present the poster “Vitamin B12 deprivation does not phenocopy selective cytotoxicity of CD320 and LRP2 silencing” at the University of Massachusetts (UMass) T.H. Chan Medical School’s fifth annual RNA+Therapeutics+Symposium June 21-23, 2023, in Worcester, MA.